We aimed to determine the incidence, treatment regimen, and outcomes (including progression-free survival overall survival) of gynecologic carcinosarcoma, a rare, aggressive, understudied malignancy. This retrospective review included all patients with cancers diagnosed treated at single tertiary care comprehensive cancer center between January 2012 May 2021. A total 2116 were eligible for revi...

Longitudinally extensive transverse myelitis (LETM) is an unusual manifestation of systemic malignancy. It has been mainly reported with lung cancers and lymphoproliferative malignancy. LETM in systemic malignancy can be caused by either intramedullary metastases or paraneoplastic syndrome. We report an unusual case of small-cell carcinoma lung, who presented with LETM without having any cardin...

Rapid progression to metastatic disease and an intrinsic resistance to any type of systemic therapy are hallmarks of aggressive solid cancers. The molecular basis for this phenotype is not clear. A detailed study of the somatic progression from local to early systemic esophageal cancer revealed rapid diversification of cancer cells isolated from various sites, but also evidence for early clonal...

A number of very interesting studies presented this year at the ASCO (American Society of Clinical Oncology) Annual Meeting, the ASCO-GU (ASCO Genitourinary Cancers) Spring Meeting, and the ESMO (European Society for Medical Oncology) Annual Congress could strongly influence or even revolutionize the systemic treatment of advanced renal cell carcinoma (RCC). The aim of this article is to identi...

Purpose Intratumoral immune activation can induce systemic immunity and anti-tumor activity. Imiquimod is a creamformulated, TLR-7 agonist that is FDA-approved for the treatment of non-melanoma skin cancers, but has limited activity against melanoma. In the current study, we studied the anti-tumor activity and mechanism of action of a novel injectable TLR 7/8 dual agonist, 3M-052, which remains...

The third most common cancer in the United States, lung cancer, is the leading cancer killer of both men and women.[1] Because of the low cure rate (14%), lung cancer kills more individuals than cancers of the breast, prostate, colorectum, and ovary combined.[1] Less than 25% of lung cancer patients present with stages I and II, and nearly all patients die with disseminated systemic disease. Th...

The aim of this article is to carry out a systematic analysis the literature concerning diagnosis oral cancers by salivary samples. Different biomarkers, produced tumor itself or its environment, show significant variations in their concentration at level, correlated not blood tissue level. After studying 239 articles, we included 36 analysis. This allowed us extract 46 potential molecules for ...

Salivary gland cancers (SGCs) are rare, accounting for less than 5% of all malignancies the head and neck region, morphologically heterogeneous. The diagnosis is mainly based on histology, with complementary aid molecular profiling, which helpful in recognizing some poorly differentiated, borderline, or atypical lesions. Instrumental imaging defines diagnosis, representing a remarkable tool tre...